全文获取类型
收费全文 | 390篇 |
免费 | 46篇 |
专业分类
儿科学 | 1篇 |
妇产科学 | 7篇 |
基础医学 | 27篇 |
口腔科学 | 8篇 |
临床医学 | 35篇 |
内科学 | 48篇 |
皮肤病学 | 1篇 |
神经病学 | 10篇 |
特种医学 | 3篇 |
外科学 | 72篇 |
综合类 | 4篇 |
一般理论 | 3篇 |
预防医学 | 109篇 |
眼科学 | 2篇 |
药学 | 13篇 |
肿瘤学 | 93篇 |
出版年
2024年 | 1篇 |
2023年 | 3篇 |
2022年 | 3篇 |
2021年 | 6篇 |
2020年 | 7篇 |
2019年 | 13篇 |
2018年 | 15篇 |
2017年 | 17篇 |
2016年 | 13篇 |
2015年 | 14篇 |
2014年 | 13篇 |
2013年 | 18篇 |
2012年 | 28篇 |
2011年 | 27篇 |
2010年 | 10篇 |
2009年 | 25篇 |
2008年 | 26篇 |
2007年 | 22篇 |
2006年 | 17篇 |
2005年 | 26篇 |
2004年 | 21篇 |
2003年 | 35篇 |
2002年 | 16篇 |
2001年 | 10篇 |
2000年 | 3篇 |
1999年 | 2篇 |
1998年 | 1篇 |
1996年 | 2篇 |
1995年 | 1篇 |
1993年 | 1篇 |
1992年 | 3篇 |
1991年 | 1篇 |
1990年 | 1篇 |
1989年 | 2篇 |
1985年 | 3篇 |
1983年 | 1篇 |
1981年 | 2篇 |
1979年 | 2篇 |
1978年 | 2篇 |
1977年 | 2篇 |
1976年 | 2篇 |
1975年 | 1篇 |
1974年 | 5篇 |
1973年 | 2篇 |
1971年 | 2篇 |
1969年 | 2篇 |
1968年 | 1篇 |
1966年 | 1篇 |
1905年 | 2篇 |
1904年 | 3篇 |
排序方式: 共有436条查询结果,搜索用时 31 毫秒
1.
Cécile Vicier Lillian Werner Jonathan Chipman Lauren C. Harshman Dattatraya H. Patil Raina N. Fichorova Jennifer R. Rider Martin G. Sanda Lorelei A. Mucci Christopher J. Sweeney 《Clinical genitourinary cancer》2019,17(1):32-37
Background
Inflammation and infections have been associated with prostate cancer progression. We assessed whether elevated serum cytokines or T. vaginalis seropositivity at the time of diagnosis was associated with higher grade or lethal prostate cancer.Patients and Methods
Men with localized or metastatic prostate cancer were included in this study. Cytokine serum levels including interleukin (IL)-1α, IL-1β, IL-2, IL-6, IL-8, monocyte chemotactic protein 1 (CCL-2), tumor necrosis factor α, and growth-regulated oncogene α (CXCL-1) using a multiplex enzyme-linked immunosorbent assay and T. vaginalis serology were measured in blood samples at diagnosis.Results
A total of 324 patients were identified at time of localized disease and 118 at time of metastatic disease. Of the 189 patients with localized disease and clinical follow-up data (median, 73 months), 28 developed lethal disease. There was no association between circulating cytokine levels above median concentrations nor T. vaginalis seropositivity and risk of intermediate- to high-risk or lethal prostate cancer.Conclusion
Higher levels of serum cytokine levels and T. vaginalis seropositivity at diagnosis are not associated with high-grade or lethal prostate cancer and do not aid risk stratification of localized prostate cancer. 相似文献2.
Karen Hunka Oksana Suchowersky Susan Wood Lorelei Derwent Zelma H T Kiss 《The Journal of neuroscience nursing》2005,37(4):204-210
The use of deep brain stimulation (DBS) to treat movement disorders such as Parkinson's disease, essential tremor, and dystonia is increasing. Although some published literature describes the methods for DBS programming, the time and nursing requirements to run a DBS surgical program have not been examined previously. For this study, we prospectively recorded the time required for both assessments and programming of the DBS from the preoperative period to 1 year after surgery in a variety of patients. Results showed that the mean total time spent programming the stimulator and assessing these patients ranged from 18.0-36.2 hours per patient. It took twice as long to program the stimulator in patients with Parkinson's disease as it did in patients with essential tremor or dystonia. When setting up a program for movement disorders surgery, nursing time spent on patient assessment and programming should be considered in the workload. 相似文献
3.
4.
Benjamin C. Fu Fred K. Tabung Claire H. Pernar Weike Wang Amparo G. Gonzalez-Feliciano Ilkania M. Chowdhury-Paulino Steven K. Clinton Edmund Folefac Mingyang Song Adam S. Kibel Edward L. Giovannucci Lorelei A. Mucci 《European urology》2021,79(3):405-412
BackgroundHyperinsulinemia and inflammation are inter-related pathways that link diet with the risk of several chronic diseases. Evidence suggests that these pathways may also increase prostate cancer risk.ObjectiveTo determine whether hyperinsulinemic diet and inflammatory diet are associated with prostate cancer incidence and mortality.Design, setting, and participantsWe prospectively followed 41 209 men in the Health Professionals Follow-up Study (1986–2014). Scores for two validated dietary patterns were calculated from food frequency questionnaires at baseline and updated every 4 yr.Outcome measurements and statistical analysisTotal, advanced, and lethal prostate cancer outcomes were assessed. Multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were determined for associations between two empirical hypothesis-oriented dietary patterns—empirical dietary index for hyperinsulinemia and empirical dietary inflammatory pattern—and prostate cancer risk estimated using Cox proportional hazard regression.Results and limitationsDuring 28 yr of follow-up, 5929 incident cases of total prostate cancer, including 1019 advanced and 667 fatal, were documented. In multivariable-adjusted models, there was a 7% higher risk of advanced prostate cancer (HR: 1.07; 95% CI: 1.01–1.15) and a 9% higher risk of fatal prostate cancer (HR: 1.09; 95% CI: 1.00–1.18) per standard deviation (SD) increase in the hyperinsulinemic diet. When stratified by age, the hyperinsulinemic diet was associated with only earlier-onset aggressive prostate cancer (men under 65 yr), with per SD HRs of 1.20 (95% CI: 1.06–1.35) for advanced, 1.22 (1.04–1.42) for fatal, and 1.20 (1.04–1.38) for lethal. The inflammatory diet was not associated with prostate cancer risk in the overall study population, but was associated with earlier-onset lethal prostate cancer (per SD increase HR: 1.16; 95% CI: 1.00–1.35).ConclusionsHyperinsulinemia and inflammation may be potential mechanisms linking dietary patterns with the risk of aggressive prostate cancer, particularly earlier-onset disease.Patient summaryAvoiding inflammatory and hyperinsulinemic dietary patterns may be beneficial for the prevention of clinically relevant prostate cancer, especially among younger men. 相似文献
5.
The ability of the VentrAssist blood pump to perform at its optimum design point is determined by a number of factors such as geometry of the pump, surface roughness, and fluid properties. Once the fluid properties are known, the performance characteristics of the pump can be optimized for that fluid. It is important to understand the effects of dynamic viscosity mu (called simply viscosity hereafter) on the performance characteristics and stability of the pump. The performance envelope of the pump and the needs of the patient must be matched. The VentrAssist pump has no shaft, seals, or fixed bearings and relies on the fluid-dynamic forces to maintain its effective performance. A number of different fluids have been tested to determine the effects of viscosity and density on pump performance. These include aqueous glycerol, red blood cells (RBCs) suspended in phosphate buffered saline solution (PBS), and Haemaccel. The effects of viscosity on the bearing stiffness, stage efficiency, and the pressure-flow rate (HQ) are characterized. The experimental results show a slight increase in the pressure rise across the pump shown as a positive upward shift of the H-Q curves with a decrease in viscosity; however, this is relatively small. A paradox in system efficiency exists: for a given fluid asymptotic viscosity, the system efficiency (product of magnetic and stage efficiency) using Haemaccel or PBS is greater than for the same viscosity of aqueous glycerol. 相似文献
6.
A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. 总被引:4,自引:0,他引:4
Grace K Dy James P Thomas George Wilding Laura Bruzek Sumithra Mandrekar Charles Erlichman Dona Alberti Kim Binger Henry C Pitot Steven R Alberts Lorelei J Hanson Rebecca Marnocha Kendra Tutsch Scott H Kaufmann Alex A Adjei 《Clinical cancer research》2005,11(9):3410-3416
PURPOSE: To define the toxicities, pharmacodynamics, and clinical activity of the proteasome inhibitor, PS-341 (bortezomib), in patients with advanced malignancies. PATIENTS AND METHODS: Twenty-eight patients (14 male and 14 female) received PS-341 twice weekly for 4 of 6 weeks (schedule I). Because toxicity necessitated dose omissions on this schedule, 16 additional patients (12 male and 4 female) received PS-341 twice weekly for 2 of every 3 weeks (schedule II). A total of 73 courses of treatment was given (median, 2; range, 1-4). Inhibition of 20S proteasome activity in peripheral blood mononuclear cells (PBMC) and accumulation of proteasome-targeted polypeptides in tumor tissue were evaluated as pharmacodynamic markers of PS-341 activity. RESULTS: The most common toxicity was thrombocytopenia, which was dose limiting at 1.7 mg/m2 (schedule I) and 1.6 mg/m2 (schedule II), respectively. Sensory neuropathy was dose-limiting in a patient in schedule I. Grade > or =3 toxicities for schedule I were constipation, fatigue, myalgia, and sensory neuropathy. Grade > or =3 toxicities for schedule II were dehydration resulting from diarrhea, nausea and vomiting, fatigue, hypoglycemia, and hypotension. The maximum tolerated dose was 1.5 mg/m2 for both schedules. Reversible dose-dependent decreases in 20S proteasome activity in PBMCs were observed, with 36% inhibition at 0.5 mg/m2, 52% at 0.9 mg/m2, and 75% at 1.25 mg/m2. Accumulation of proteasome-targeted polypeptides was detected in tumor samples after treatment with PS-341. A patient with multiple myeloma had a partial response. CONCLUSION: PS-341 given 1.5 mg/m2 twice weekly for 2 of every 3 weeks is well tolerated and should be further studied. 相似文献
7.
8.
9.
10.
Mehta RH Harjai KJ Cox DA Stone GW Brodie BR Boura J Grines L O'Neill W Grines CL;Primary Angioplasty in Myocardial Infarction investigators 《The American journal of cardiology》2005,96(7):901-906
Little is known about the influence of stenting versus balloon angioplasty on long-term outcomes (particularly mortality) after primary percutaneous coronary intervention (PCI). We evaluated 2,087 patients with ST-elevation myocardial infarction enrolled in various Primary Angioplasty in Myocardial Infarction (PAMI) trials in the United States, who underwent primary PCI. The main outcome was all-cause mortality at 5 years, obtained through the National Death Index. Of the 2,087 patients, stenting was performed in 692 (33%). The absolute difference in the hospital (2.2% vs 3.3%), 1-year (3.3% vs 5.2%), and 5-year (10% vs 13%) mortality rates favored patients receiving a stent versus conventional balloon therapy, with the difference increasing with time. A multivariate Cox model identified stent use (vs balloon alone) as an independent correlate of lower 5-year mortality (hazard ratio 0.60, 95% confidence interval 0.42 to 0.85). The absolute reduction in mortality was greatest in the highest risk group. In conclusion, compared with balloon angioplasty, stenting during primary PCI not only resulted in better angiographic and short-term outcomes, but also in a sustained beneficial effect on mortality at 5 years. These data support the routine use of coronary stenting in most patients undergoing primary PCI, when feasible. 相似文献